[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342164-105":59,"doc-detail-342164-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","novel-benzothiazolebenzothiazole-thiazolidine24dione-derivatives-as-potential-foxm1-inhibitors-in-silico-synthesis-and-in-vitro-studies","Novel benzothiazole/benzothiazole thiazolidine‐2,4‐dione derivatives as potential FOXM1 inhibitors - In silico, synthesis, and in vitro studies","","The oncogenic transcription factor FOXM1 is overexpressed in breast and other solid cancers, driving tumor growth and progression via complex molecular interactions and making it an attractive targeted-therapy candidate. Although small-molecule FOXM1 inhibitors exist, limited specificity, potency, and clinical efficacy restrict translation. To discover effective inhibitors, researchers synthesized novel benzothiazole derivatives (KC10–KC13) and benzothiazole–thiazolidine-2,4-dione hybrids (KC21–KC36), then assessed FOXM1 inhibition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/novel-benzothiazolebenzothiazole-thiazolidine24dione-derivatives-as-potential-foxm1-inhibitors-in-silico-synthesis-and-in-vitro-studies/342164/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/novel-benzothiazolebenzothiazole-thiazolidine24dione-derivatives-as-potential-foxm1-inhibitors-in-silico-synthesis-and-in-vitro-studies/342164.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is FOXM1 considered a promising therapeutic target for solid cancers?","Question",{"text":112,"@type":113},"FOXM1 is an oncogenic transcription factor frequently overexpressed in breast and other solid cancers and acts as a key driver of tumor growth and progression, including proliferation and progression-related processes. Its central role makes it attractive for targeted therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What compounds were synthesized to identify potential FOXM1 inhibitors?",{"text":117,"@type":113},"The study synthesized benzothiazole derivatives (KC10–KC13) and benzothiazole hybrids with thiazolidine-2,4-dione (KC21–KC36). These were evaluated for FOXM1 inhibition.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the in vitro experiments show regarding FOXM1 inhibition?",{"text":121,"@type":113},"In vitro testing on the MDA-MB-231 breast cancer cell line showed that KC12, KC21, and KC30 significantly inhibited FOXM1. Their potency exceeded the reference compound FDI-6, with reported IC50 values of 6.13, 10.77, and 12.86 µM versus 20.79 µM for FDI-6.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342164,1790189393,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","DOI: 10.1002/ardp.202400504  \nFULL PAPE R  \nNovel benzothiazole/benzothiazole thiazolidine‐2,4‐dione derivatives as potential FOXM1 inhibitors: In silico, synthesis, and in vitro studies  \nKhaled A. N. Abusharkh1,2,3 | Ferah Comert Onder4  | Venhar Çınar5 |  \nAlper Onder2 | Merve Sıkık6  | Zuhal Hamurcu5 | Bulent Ozpolat7 | Mehmet Ay2  1Department of Chemistry, School of Graduate Studies, Çanakkale Onsekiz Mart University, Çanakkale, Türkiye  \n2Department of Chemistry, Natural Products and Drug Research Laboratory, Faculty of Science, Çanakkale Onsekiz Mart University, Çanakkale, Türkiye  \n3Department of Chemistry and Chemical Technology, Faculty of Science and Technology, Al‐Quds University, East Jerusalem, Palestine 4Department of Medical Biology, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale, Türkiye  \n5Department of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye  \n6Department of Medical System Biology, School of Graduate Studies, Çanakkale Onsekiz Mart University, Çanakkale, Türkiye 7Department of Nanomedicine, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA  \nCorrespondence  \nFerah Comert Onder, Department of Medical Biology, Faculty of Medicine, Çanakkale Onsekiz Mart University, 17020 Çanakkale, Türkiye.  \nEmail: [ferahcomertonder@comu.edu.tr](ferahcomertonder@comu.edu.tr)  \nBulent Ozpolat, Department of Nanomedicine, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030‐2707, USA.  \nEmail: [bozpolat@houstonmethodist.org](bozpolat@houstonmethodist.org)  \nMehmet Ay, Department of Chemistry, Natural Products and Drug Research Laboratory, Faculty of Science, Çanakkale Onsekiz Mart University, 17020 Çanakkale, Türkiye. [Email:](Email: mehmetay06@comu.edu.tr)[ mehmetay06@comu.edu.tr](Email: mehmetay06@comu.edu.tr)  \nFunding information  \nAl‐Quds University; Council of Higher Education of Türkiye (YÖK Palestine Scholarship); Çanakkale Onsekiz Mart University Research Coordination Unit, Grant/Award Number: FDK‐2022‐4145  \nAbstract  \nThe oncogenic transcription factor FOXM1 overexpressed in breast and other solid cancers, is a key driver of tumor growth and progression through complex interactions, making it an attractive molecular target for the development of targeted therapies. Despite the availability of small‐molecule inhibitors, their limited specificity, potency, and efficacy hinder clinical translation. To identify effective FOXM1 inhibitors, we synthesized novel benzothiazole derivatives (KC10–KC13) and benzothiazole hybrids with thiazolidine‐2,4‐dione (KC21–KC36). These compounds were evaluated for FOXM1 inhibition. Molecular docking and molecular dynamics simulation analysis revealed their binding patterns and affinities for the FOXM1‐DNA binding domain. The interactions with key amino acids such as Asn283, His287, and Arg286, crucial for FOXM1 inhibition, have been determined with the synthesized compounds. Additionally, the molecular modeling study indicated that KC12, KC21, and KC30 aligned structurally and interacted similarly to the reference compound FDI‐6. In vitro studies with the MDA‐MB‐231 breast cancer cell line demonstrated that KC12, KC21, and KC30 significantly inhibited FOXM1, showing greater potency than FDI‐6, with IC50 values of 6.13, 10.77, and 12.86 µM, respectively, versus 20.79 µM for FDI‐6. Our findings suggest that KC12, KC21, and KC30 exhibit strong activity as FOXM1 inhibitors and may be suitable for in vivo animal studies.  \nKEYWO R DS  \nBenzothiazole, FOXM1 inhibitors, In vitro, MD simulation, TNBC  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2024 The Author(s) . Archiv der Pharmazie published by Wiley‐VCH GmbH on be","cbCaifWeJtXNOcm2","https://ap.wps.com/l/cbCaifWeJtXNOcm2","pdf",6890721,27,"English","# Introduction\n## FOXM1 as a regulator in cancer progression\n## Relevance to breast cancer and TNBC\n## Rationale for developing FOXM1 inhibitors","[{\"question\":\"Why is FOXM1 considered a promising therapeutic target for solid cancers?\",\"answer\":\"FOXM1 is an oncogenic transcription factor frequently overexpressed in breast and other solid cancers and acts as a key driver of tumor growth and progression, including proliferation and progression-related processes. Its central role makes it attractive for targeted therapies.\"},{\"question\":\"What compounds were synthesized to identify potential FOXM1 inhibitors?\",\"answer\":\"The study synthesized benzothiazole derivatives (KC10–KC13) and benzothiazole hybrids with thiazolidine-2,4-dione (KC21–KC36). These were evaluated for FOXM1 inhibition.\"},{\"question\":\"What did the in vitro experiments show regarding FOXM1 inhibition?\",\"answer\":\"In vitro testing on the MDA-MB-231 breast cancer cell line showed that KC12, KC21, and KC30 significantly inhibited FOXM1. Their potency exceeded the reference compound FDI-6, with reported IC50 values of 6.13, 10.77, and 12.86 µM versus 20.79 µM for FDI-6.\"}]","Novel benzothiazole/benzothiazole thiazolidine‐2,4‐dione derivatives as potential FOXM1 inhibitors - In silico, synthesis, and in vitro studies | PDF",1790045627,68,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15da45b4ffe3e98d99514b73dec39e24.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b472c98afcaee15182cbfafda62c1d5e.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c734381210f7059b80acc12db5fab27f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eeb60758ae67a308a2518ae85d2e63c6.webp",980,1287]